Member Info for Fruitsnveg

RE: Covid-19 variant JN.1 may be the mildest form of the virus yet - NATURE 15/1/24Today 14:39

That may be your inexpert opinion SPacDan, the national NHS chief clearly disagrees with you! Hot off the press...:

"NHS national medical director, professor Sir Stephen Powis, has warned the situation could get even worse with this week’s cold weather poised to fuel a surge in those being hospitalised.

He said: “These figures show this continues to be a challenging winter, with our staff facing a combination of considerable pressures including winter viruses, high bed occupancy and the knock-on effects from strikes, while this week’s cold snap could see a jump in the number of people needing care.”

Recent data suggests a new and particularly immune-evasive coronavirus variant is responsible for the majority of new cases in England. The JN.1 variant – named “Juno” – was responsible for 62 per cent of the Covid samples sequenced in the final week of 2023, a report by the UK Health Security Agency (UKHSA) revealed last week.

A number of hospitals have also been forced to reintroduce mask wearing due to the increase in Covid and other winter viruses circulating.

Meanwhile, the number of patients in hospital with flu each day last week decreased slightly from 1,548 to 1,416, but is still up from 991 in the last week of December.

https://www.independent.co.uk/news/health/covid-norovirus-juno-hospital-admissions-nhs-b2480733.html

That may be your inexpert opinion SPacDan, the national NHS chief clearly disagrees with you! Hot off the press...:

"NHS national medical director, professor Sir Stephen Powis, has warned the situation could get even worse with this week’s cold weather poised to fuel a surge in those being hospitalised.

He said: “These figures show this continues to be a challenging winter, with our staff facing a combination of considerable pressures including winter viruses, high bed occupancy and the knock-on effects from strikes, while this week’s cold snap could see a jump in the number of people needing care.”

Recent data suggests a new and particularly immune-evasive coronavirus variant is responsible for the majority of new cases in England. The JN.1 variant – named “Juno” – was responsible for 62 per cent of the Covid samples sequenced in the final week of 2023, a report by the UK Health Security Agency (UKHSA) revealed last week.

A number of hospitals have also been forced to reintroduce mask wearing due to the increase in Covid and other winter viruses circulating.

Meanwhile, the number of patients in hospital with flu each day last week decreased slightly from 1,548 to 1,416, but is still up from 991 in the last week of December.

https://www.independent.co.uk/news/health/covid-norovirus-juno-hospital-admissions-nhs-b2480733.html

Here you go DocD, saves you digging around -

"JN.1's parent can infect lung cells more efficiently, a mutation that's different from the "milder" Omicron"

"According to CDC estimates, nearly 61 percent of COVID-19 cases are infections with the JN.1 strain. Over the course of one month, JN.1 went from being the third most prevalent strain in the U.S., after EG.5 and HV.1., to No. 1. Experts have previously said that JN.1 is largely contributing to this year’s surge of winter illnesses as COVID-19 hospitalizations and deaths are on the rise in some parts of the country."

https://www.salon.com/2024/01/12/more-severe-disease-symptoms/?s=35

By "Doc" I mean Docdan, not to be confused with Doc83.

I suggested you take on more research yourself Doc instead of relying on the goodwill of others, how is that going?

I share with the genuinely invested. Maybe drop Consilium a line when Mani is finished dusting the Olivetti?

Funnily enough, it's quite different to the one I received. Now that is a mystery.....

Thanks Tim "New to this Stock, worth a Punt?". I've never known such dedication from a a non-invested punting person.

Lol

Excellent. So many parallels as you say.

Interesting ferret comment. Suggest you go and do your own research Doc.Dan, no reason why I or others should do the grunt work anymore for you? You have questions that you want answered? Time to roll up those slippery sleeves and dig.

TP, that study has been superseded in 2023. NIH, new guidelines for clinicians. Available on t'internet. I'm sure between you and SpacDaneeka you can find it and bury any positive content quite skillfully.

I know it's been done Doc.Dan, that's what I said. Do keep up.

No Ernie :-)

And it's recently been published (Nov 23). It appears the UoS team have been very busy!!

Good study which shows it's been done. Although it is for surfactant, it nonetheless found the use of "novel breath-synchronised delivery" using a "vibrating mesh nebulizer in mechanically ventilated patients". There are further studies on other aerosolized treatments which also show efficient delivery of drug to the lungs.

Just my opinion but I would say the ventilated patients would be very carefully selected (risk v benefit) as the right targets likely to respond. I wouldn't see it as a 'give everyone on a ventilator a puff' thing. I think that would be risky and wasteful. You want to give the right patient the right drug at the right time, IMHO.

The study of nebulized medications to ventilated patients is not new, nor is it lacking in data, so I would guess that the regulators won't baulk. Ventillated patients receive all manner of treatments, some nebulized, such as aerosolized antibiotics. Of course there will be strict technical requirements to be followed when treating these patients, and risk, but that goes with most treatments on hospitalised patients.

There's so much you don't know SpacDaneeka. And it's clear that really irks you..... Ho hum.

I'm not in the leas bit worried about a funding solution. Whatever fretful nonsense you're selling today, I'm not buying it. You inferred that the regulator could stop us from bringing our drug to market without proof of funding. They don't worry about such silliness. If the drug is worthy of approval, rest assured, there won't be a shortage of £ backers.

PS: Where's Doc.Dan, or can't you both post using the same keyboard at the same time, lol.

Your arguments get more ridiculous as the days go on Spacdaneeka.

You are mixing up Regulator role versus Investor role.

NOWHERE is it written that the regulator has any oversight for the "trial applicant’s capacity to bring the product to market". That is just made up nonsense.

The regulator does not care about the funding of a company, not does it have any say in company finances.. Their interest lies in all things drug, not commercial viability. If that was the case, many drugs would have never made it to market, much less one with blockbuster potential.

Https://www.dailymail.co.uk/health/article-12964925/World-leaders-meet-Davos-thrash-plan-protect-against-Disease-X-hypothetical-pandemic-kill-20-times-people-Covid.html

"World leaders meet in Davos to thrash out plan to protect against 'Disease X' - a hypothetical pandemic that could kill 20-times more people than Covid. Disease X represents a hypothetical, currently unknown pathogen. It was added to the WHO's list of nine priority diseases in 2018."

"DailyMail.com previously spoke to three virus experts who agreed a respiratory virus — spread via droplets from coughs and sneezes — was most likely to trigger the next fast-spreading disease that causes a global shutdown."

It's good to see that the Davos crowd remain focussed on finding future antivirals to combat the next pandemic.